Decisions / 4714
final resolution2021-02-18active

Arzneimittel-Richtlinie/Anlage XII: Entrectinib (ROS1-positives, fortgeschrittenes nicht kleinzelliges Lungenkarzinom)

Open official decision page ↗

G-BA source · retrieved 2026-08-05

Structured conclusion

Final result by patient group

1 source-verified result

Patient group

Erwachsene Patienten mit ROS1-positivem, fortgeschrittenem nicht‐kleinzelligen Lungenkarzinom (NSCLC), die nicht mit ROS1-Inhibitoren vorbehandelt wurden

Added benefit not proven

Comparator
Crizotinib

Open official result PDF ↗

Decision orientation

What the G-BA did

4 cited claims

Each claim links to the official G-BA page or an exact PDF page range.

Official metadata

Decision date
2021-02-18
Effective
18.02.2021
Action type
final resolution
Committee
Arzneimittel

Case context

Listed normative targets

directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V

A listed target is not treated as a new directive version unless an official version source exists.

Official document package